F. Schnitzler, H. Fidder, M. Ferrante, M. Noman, I. Arijs et al.,

, Long-term outcome of treatment with infliximab in 614 patients with Crohn"s disease: results from a single-centre cohort, Gut. 1 avr, vol.58, issue.4, pp.492-500, 2009.

D. C. Baumgart and W. J. Sandborn, Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet. mai, vol.369, pp.1641-57, 2007.

J. Colombel, W. J. Sandborn, P. Rutgeerts, R. Enns, S. B. Hanauer et al., Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn"s Disease: The CHARM Trial, Gastroenterology. janv, vol.132, issue.1, pp.52-65, 2007.

W. J. Sandborn, S. B. Hanauer, P. Rutgeerts, R. N. Fedorak, M. Lukas et al.,

D. G. , Adalimumab for maintenance treatment of Crohn"s disease: results of the CLASSIC II trial, Gut. 5 avr, vol.56, issue.9, pp.1232-1241, 2007.

S. R. Targan, S. B. Hanauer, S. J. Van-deventer, L. Mayer, and D. H. Present,

T. , A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor ? for Crohn"s disease, N Engl J Med, vol.337, issue.15, pp.1029-1036, 1997.

W. J. Sandborn, B. G. Feagan, S. Stoinov, P. J. Honiball, P. Rutgeerts et al., Certolizumab pegol for the treatment of Crohn"s disease, N Engl J Med, vol.357, issue.3, pp.228-238, 2007.

S. B. Hanauer, W. J. Sandborn, P. Rutgeerts, R. N. Fedorak, M. Lukas et al., Human Anti-Tumor Necrosis Factor Monoclonal Antibody

B. E. Sands, F. H. Anderson, C. N. Bernstein, W. Y. Chey, B. G. Feagan et al., Infliximab maintenance therapy for fistulizing Crohn"s disease, Trial. Gastroenterology. févr, vol.130, issue.2, pp.876-885, 2004.

B. E. Sands, M. A. Blank, R. H. Diamond, J. P. Barrett, and S. J. Deventer, Maintenance infliximab does not result in increased abscess development in fistulizing Crohn"s disease: results from the ACCENT II study, Aliment Pharmacol Ther. avr, vol.23, issue.8, pp.1127-1163, 2006.

S. Hanauer, Maintenance infliximab for Crohn"s disease : the ACCENT I randomised trial. The Lancet, p.1539, 2002.

A. M. Peterson, D. P. Nau, J. A. Cramer, J. Benner, F. Gwadry-sridhar et al., A Checklist for Medication Compliance and Persistence Studies Using Retrospective Databases. Value Health, janv, vol.10, issue.1, pp.3-12, 2007.

J. A. Cramer, A. Roy, A. Burrell, C. J. Fairchild, M. J. Fuldeore et al.,

, Medication Compliance and Persistence: Terminology and Definitions, Value Health. janv, vol.11, issue.1, pp.44-51, 2008.

J. Cosnes, H. Sokol, A. Bourrier, I. Nion-larmurier, A. Wisniewski et al., Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn"s disease, Aliment Pharmacol Ther sept, 2016.

Å. Riis, T. C. Martinsen, H. L. Waldum, and R. Fossmark, Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn"s disease, Scand J Gastroenterol. juin, vol.47, issue.6, pp.649-57, 2012.

S. Singh, H. C. Heien, L. R. Sangaralingham, S. R. Schilz, M. D. Kappelman et al., Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn"s Disease, Clin Gastroenterol Hepatol. août, vol.14, issue.8, pp.1120-1129, 2016.

M. T. Osterman, K. Haynes, E. Delzell, J. Zhang, M. Bewtra et al.,

, Comparative Effectiveness of Infliximab and Adalimumab for Crohn"s Disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. mai, vol.12, issue.5, pp.811-817, 2014.

F. Zorzi, S. Zuzzi, S. Onali, E. Calabrese, G. Condino et al., Efficacy and safety of infliximab and adalimumab in Crohn"s disease: a single centre study, Aliment Pharmacol Ther. 1 juin, vol.35, issue.12, pp.1397-407, 2012.

L. Peyrin-biroulet, E. V. Loftus, J. Colombel, and W. J. Sandborn, The natural history of adult Crohn"s disease in population-based cohorts, Am J Gastroenterol, vol.105, issue.2, pp.289-297, 2010.

L. Peyrin-biroulet and F. Depont-hebert, Productivité individuelle et maladie de Crohn: impact de la maladie et apport des traitements, Hépato-Gastro Oncol Dig, vol.20, pp.20-24, 2013.

B. Khor, A. Gardet, and R. J. Xavier, Genetics and pathogenesis of inflammatory bowel disease, Nature. 15 juin, vol.474, issue.7351, pp.307-324, 2011.

D. R. Gaya, R. K. Russell, E. R. Nimmo, and J. Satsangi, New genes in inflammatory bowel disease: lessons for complex diseases? The Lancet, vol.367, pp.1271-1284, 2006.

S. S. Mahid, K. S. Minor, R. E. Soto, C. A. Hornung, and S. Galandiuk, Smoking and Inflammatory Bowel Disease: A Meta-analysis, Mayo Clin Proc. nov, vol.81, issue.11, pp.1462-71, 2006.

P. López-serrano, J. L. Pérez-calle, M. T. Pérez-fernández, J. M. Fernández-font, D. Boixeda-de-miguel et al., Environmental risk factors in inflammatory bowel diseases. Investigating the hygiene hypothesis: A Spanish casecontrol study, Scand J Gastroenterol. déc, vol.45, issue.12, pp.1464-71, 2010.

S. Soon, N. A. Molodecky, D. M. Rabi, W. A. Ghali, H. W. Barkema et al., The relationship between urban environment and the inflammatory bowel diseases: a systematic review and meta-analysis, BMC Gastroenterol, vol.12, issue.1, p.1, 2012.

L. Laszlo, Striking elevation in incidence and prevalence of inflammmatory bowel disease in a province of western Hungary between 1977-2001, World J Gastroenterol, vol.10, issue.3, pp.404-409

K. O. Gradel, H. L. Nielsen, H. C. Schønheyder, T. Ejlertsen, B. Kristensen et al., Increased Short-and Long-Term Risk of Inflammatory Bowel Disease After Salmonella or Campylobacter Gastroenteritis, Gastroenterology. août, vol.137, issue.2, pp.495-501, 2009.

E. A. Mann and S. A. Saeed, Gastrointestinal infection as a trigger for inflammatory bowel disease, Curr Opin Gastroenterol. janv, vol.28, issue.1, pp.24-33, 2012.

A. Darfeuille-michaud, J. Boudeau, P. Bulois, C. Neut, A. Glasser et al., High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn"s disease, Gastroenterology. août, vol.127, issue.2, pp.412-433, 2004.

M. D. Kappelman, S. L. Rifas-shiman, K. Kleinman, D. Ollendorf, A. Bousvaros et al., The Prevalence and Geographic Distribution of Crohn"s Disease and Ulcerative Colitis in the United States, Clin Gastroenterol Hepatol. déc, vol.5, issue.12, pp.1424-1433, 2007.

S. Shivananda, J. Lennard-jones, R. Logan, N. Fear, A. Price et al., Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD), Gut, vol.39, issue.5, pp.690-697, 1996.

C. Gower-rousseau, F. Vasseur, M. Fumery, G. Savoye, J. Salleron et al., Epidemiology of inflammatory bowel diseases: New insights from a French population-based registry (EPIMAD), Dig Liver Dis. févr, vol.45, issue.2, pp.89-94, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01701899

V. Chouraki, G. Savoye, L. Dauchet, G. Vernier-massouille, J. Dupas et al., The changing pattern of Crohn"s disease incidence in northern France: a continuing increase in the 10-to 19-year-old age bracket, Epidemiology of inflammatory bowel disease, vol.33, pp.1133-1175, 1988.

F. Molinie, Opposite evolution in incidence of Crohn"s disease and ulcerative colitis in Northern France (1988-1999), Gut. 1 juin, vol.53, issue.6, pp.843-851, 2004.

M. Henriksen, J. Jahnsen, I. Lygren, E. Aadland, T. Schulz et al.,

, Clinical course in Crohn"s disease: Results of a five-year population-based follow-up study (the IBSEN study), Scand J Gastroenterol. janv, vol.42, issue.5, pp.602-612, 2007.

P. Munkholm, E. Langholz, M. Davidsen, and V. Binder, Disease activity courses in a regional cohort of Crohn"s disease patients, Scand J Gastroenterol. juill, vol.30, issue.7, pp.699-706, 1995.

V. Binder, C. Hendriksen, and S. Kreiner, Prognosis in Crohn"s disease-based on results from a regional patient group from the county of Copenhagen, Gut, vol.26, issue.2, pp.146-150, 1985.

D. A. Schwartz, Diagnosis and Treatment of Perianal Fistulas in Crohn Disease

, Ann Intern Med, vol.135, issue.10, p.906, 2001.

F. L. Wolters, Phenotype at diagnosis predicts recurrence rates in Crohn"s disease. Gut. 27 sept, vol.55, pp.1124-1154, 2005.

L. Peyrin-biroulet, E. V. Loftus, J. Colombel, and W. J. Sandborn, The natural history of adult Crohn"s disease in population-based cohorts, Am J Gastroenterol. févr, vol.105, issue.2, pp.289-97, 2010.

W. A. Faubion, E. V. Loftus, W. S. Harmsen, A. R. Zinsmeister, and W. J. Sandborn, The natural history of corticosteroid therapy for inflammatory bowel disease: A populationbased study, Gastroenterology. août, vol.121, issue.2, pp.255-60, 2001.

G. Olaison, K. Smedh, and R. Sjödahl, Natural course of Crohn"s disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms, Gut. 3 janv, vol.33, issue.3, pp.331-336, 1992.

D. Haens, G. R. Geboes, K. Peeters, M. Baert, F. Penninckx et al., Early lesions of recurrent Crohn"s disease caused by infusion of intestinal contents in excluded ileum, Gastroenterology. févr, vol.114, issue.2, pp.262-269, 1998.

C. Zallot and L. Peyrin-biroulet, Clinical Risk Factors for Complicated Disease: How Reliable Are They? Dig Dis, vol.30, pp.67-72, 2012.

L. Beaugerie, P. Seksik, I. Nion-larmurier, J. Gendre, and J. Cosnes, Predictors of Crohn"s Disease, Gastroenterology. mars, vol.130, issue.3, pp.650-656, 2006.

A. Dignass, G. Van-assche, J. O. Lindsay, M. Lémann, J. Söderholm et al., The second European evidence-based Consensus on the diagnosis and management of Crohn"s disease: Current management, J Crohns Colitis. févr, vol.4, issue.1, pp.28-62, 2010.

L. Peyrin-biroulet, W. S. Harmsen, W. J. Tremaine, A. R. Zinsmeister, W. J. Sandborn et al., Surgery in a Population-Based Cohort of Crohn"s Disease From Olmsted County, Minnesota (1970-2004), Am J Gastroenterol, vol.107, issue.11, pp.1693-701, 2012.

O. Bernell, A. Lapidus, and G. Hellers, Risk factors for surgery and recurrence in 907 patients with primary ileocaecal Crohn"s disease, Br J Surg. 1 déc, vol.87, issue.12, pp.1697-701, 2000.

M. Barreiro-de-acosta, J. E. Domínguez-muñoz, N. Vera, M. C. Lozano-león, A. Lorenzo et al., Relationship between clinical features of Crohn"s disease and the risk of developing extraintestinal manifestations, Eur J Gastroenterol Hepatol. janv, vol.19, issue.1, pp.73-81, 2007.

E. M. Yoshida, The Crohn"s Disease Activity Index, its derivatives and the Inflammatory Bowel Disease Questionnaire: a review of instruments to assess Crohn"s disease, Can J Gastroenterol J Can Gastroenterol. févr, vol.13, issue.1, pp.65-73, 1999.

S. Vermeire, G. Van-assche, and P. Rutgeerts, The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases, Nat Rev Gastroenterol Hepatol. déc, vol.2, issue.12, pp.580-586, 2005.

D. Haens, G. Ferrante, M. Vermeire, S. Baert, F. Noman et al.,

, Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease, Inflamm Bowel Dis. 1 déc, vol.18, issue.12, pp.2218-2242, 2012.

R. Mao, Y. Xiao, X. Gao, B. Chen, Y. He et al., Fecal calprotectin in predicting relapse of inflammatory bowel diseases: A meta-analysis of prospective studies, Inflamm Bowel Dis, vol.18, issue.10, pp.1894-1903, 2012.

J. Mary and R. Modigliani, Development and validation of an endoscopic index of the severity for Crohn"s disease: a prospective multicentre study. Groupe d, Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut, vol.30, issue.7, pp.983-989, 1989.

M. Daperno, Development and validation of a new, simplified endoscopic activity score for Crohn"s disease: the SES-CD Gastrointestinalendoscopy, vol.60, pp.505-512

P. Rutgeerts, K. Geboes, G. Vantrappen, J. Beyls, R. Kerremans et al., Predictability of the postoperative course of Crohn"s disease. Gastroenterology, vol.99, pp.956-63, 1990.

A. Jouret and J. Haot, Le granulome et le microgranulome en pathologie digestive etude critique. apport des coupes sériées et semi-sériées au diagnostic de la maladie de Crohn, Acta Endosc, vol.18, issue.1, p.35

J. Panes, Y. Bouhnik, W. Reinisch, J. Stoker, S. A. Taylor et al., Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines, J Crohns Colitis. août, vol.7, issue.7, pp.556-85, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01704202

F. Parente, S. Greco, M. Molteni, C. Cucino, G. Maconi et al., Role of early ultrasound in detecting inflammatory intestinal disorders and identifying their anatomical location within the bowel, Aliment Pharmacol Ther, vol.18, issue.10, pp.1009-1025, 2003.

T. Jess, M. Gamborg, P. Matzen, P. Munkholm, and T. Sorensen, Increased Risk of Intestinal Cancer in Crohn"s Disease: A Meta-Analysis of Population-Based Cohort Studies, Am J Gastroenterol. déc, vol.100, issue.12, pp.2724-2733, 2005.

C. Canavan, K. R. Abrams, and J. Mayberry, Meta-analysis: colorectal and small bowel cancer risk in patients with Crohn"s disease, Aliment Pharmacol Ther. 1 avr, vol.23, issue.8, pp.1097-104, 2006.

F. Magro, L. Peyrin-biroulet, H. Sokol, X. Aldeger, A. Costa et al.,

R. Modigliani, J. Y. Mary, J. F. Simon, A. Cortot, J. C. Soule et al., Efficacy of 5-Aminosalicylates in Crohn Disease: Systematic Review and Meta-Analysis-ajg201171a.pdf, Extra-intestinal malignancies in inflammatory bowel disease: Results of the 3rd ECCO Pathogenesis Scientific Workshop (III), vol.8, p.24, 2014.

, Clinical, biological, and endoscopic picture of attacks of Crohn"s disease. Evolution on prednisolone. Groupe d"Etude Thérapeutique des Affections Inflammatoires Digestives, Gastroenterology. avr, vol.98, issue.4, pp.811-819, 1990.

S. Candy, J. Wright, M. Gerber, G. Adams, M. Gerig et al., A controlled double blind study of azathioprine in the management of Crohn"s disease, Gut, vol.37, issue.5, pp.674-678, 1995.

M. C. Azathioprine, Mercaptopurine in Inflammatory Bowel Disease: Pharmacology, Efficacy, and Safety Clin Gastroenterol and Hepatol, pp.731-743, 2004.

J. F. Colombel, W. J. Sandborn, W. Reinisch, G. J. Mantzaris, and A. Kornbluth,

D. Rachmilewitz, Infliximab, azathioprine, or combination therapy for Crohn"s disease, N Engl J Med, vol.362, issue.15, pp.1383-1395, 2010.

B. G. Feagan, R. N. Fedorak, E. J. Irvine, G. Wild, L. Sutherland et al., A comparison of methotrexate with placebo for the maintenance of remission in Crohn"s disease, N Engl J Med, vol.342, issue.22, pp.1627-1632, 2000.

A. A. Alfadhli, J. W. Mcdonald, B. Feagan, B. G. Feagan, J. Rochon et al., Methotrexate for induction of remission in refractory Crohn"s disease. In: The Cochrane Collaboration, éditeur. Cochrane Database of Systematic Reviews 70

, Methotrexate for the treatment of Crohn"s disease, N Engl J Med, vol.332, issue.5, pp.292-297, 1995.

E. Stange, R. Modigliani, S. Peña, and . Wood, European Trial of Cyclosporine in Chronic Active Crohn"s Disease: A 12-Month Study, Gastroenterology, vol.109, pp.774-82, 1995.

W. J. Sandborn, B. G. Feagan, P. Rutgeerts, S. Hanauer, J. Colombel et al., Vedolizumab as Induction and Maintenance Therapy for Crohn"s Disease, N Engl J Med. 22 août, vol.369, issue.8, pp.711-732, 2013.

W. J. Sandborn, J. F. Colombel, R. Enns, B. G. Feagan, S. B. Hanauer et al., Natalizumab induction and maintenance therapy for Crohn"s disease, N Engl J Med, vol.353, issue.18, pp.1912-1925, 2005.

R. Suivi-stelara®-;-sandborn, W. J. Gasink, C. Gao, L. Blank, M. A. Johanns et al.,

, Ustekinumab Induction and Maintenance Therapy in Refractory Crohn"s Disease, N Engl J Med, vol.367, issue.16, pp.1519-1547, 2012.

G. Eissner, W. Kolch, and P. Scheurich, Ligands working as receptors: reverse signaling by members of the TNF superfamily enhance the plasticity of the immune system, Cytokine Growth Factor Rev, vol.15, issue.5, pp.353-66, 2004.

D. H. Yoo, P. Hrycaj, P. Miranda, E. Ramiterre, M. Piotrowski et al., A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study, Ann Rheum Dis, vol.72, issue.10, pp.1613-1633, 2013.

W. Park, P. Hrycaj, S. Jeka, V. Kovalenko, G. Lysenko et al., A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study, Ann Rheum Dis, vol.72, issue.10, pp.1605-1617, 2013.

S. Schreiber, J. F. Colombel, . Blommfield, . Nikolaus, P. Scholmerich et al., WJIncreased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data, Am J Gastroenterol, vol.105, pp.1574-1582, 2010.

D. H. Present, P. Rutgeerts, S. Targan, S. B. Hanauer, L. Mayer et al., Infliximab for the treatment of fistulas in patients with Crohn"s disease, N Engl J Med, vol.340, issue.18, pp.1398-1405, 1999.

L. Peyrin-biroulet, P. Deltenre, N. De-suray, J. Branche, and W. J. Sandborn,

J. Colombel, Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn"s Disease: Meta-Analysis of Placebo-Controlled Trials, Clin Gastroenterol Hepatol. juin, vol.6, issue.6, pp.644-53, 2008.

J. L. Seminerio, E. V. Loftus, J. Colombel, P. Thapa, and W. J. Sandborn, Infliximab for Crohn"s Disease: The First 500 Patients Followed Up Through, Dig Dis Sci. mars, vol.58, issue.3, pp.797-806, 2009.

H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos et al.,

, Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut. 1 avr, vol.58, issue.4, pp.501-509, 2009.

F. Carbonnel, D. Axel, and A. , Mise à jour 2014 des recommandatons ECCO sur la maladie de Crohn. Quoi de neuf?

J. Salleron, S. Danese, D. Agay, L. , P. et al., Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge, J Crohns Colitis. 31 mars, p.68, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01662135

G. S. Hazlewood, A. Rezaie, M. Borman, R. Panaccione, S. Ghosh et al., Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn

K. L. Hyrich, K. D. Watson, and M. Lunt, Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between, Symmons DPM, on behalf of the British Society for Rheumatology Biologics Register (BSRBR), vol.148, pp.117-140, 2001.

M. Fabbroni, L. Cantarini, F. Caso, L. Costa, V. A. Pagano et al., Drug Retention Rates and Treatment Discontinuation among Anti-TNF-? Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice, Mediators Inflamm, vol.2014, pp.1-7, 2014.

A. Fisher, K. Bassett, J. M. Wright, M. A. Brookhart, H. Freeman et al.,

, Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis-A Population-Based Cohort Study. Proost P, éditeur, PLoS ONE. 20 août, vol.9, issue.8, p.105193, 2014.

W. Kievit, J. Fransen, A. Oerlemans, H. H. Kuper, M. Van-der-laar et al., The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice, Ann Rheum Dis, vol.66, issue.11, pp.1473-1481, 2007.

J. D. Greenberg, G. Reed, D. Decktor, L. Harrold, D. Furst et al., A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry, Ann Rheum Dis. juill, vol.71, issue.7, pp.1134-1176, 2012.

D. C. Baumgart and W. J. Sandborn, Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet, vol.369, pp.1641-1657, 2007.

S. Danese, L. Vuitton, and L. Peyrin-biroulet, Biologic agents for IBD: practical insights, Nat Rev Gastroenterol Hepatol. 18 août, vol.12, issue.9, pp.537-582, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01667747

C. Ha, T. A. Ullman, C. A. Siegel, and A. Kornbluth, Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population, Clin Gastroenterol Hepatol. sept, vol.10, issue.9, pp.1002-1009, 2012.

M. A. Blum, D. Koo, and J. A. Doshi, Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review, Clin Ther. juill, vol.33, issue.7, pp.901-914, 2011.

A. A. Saad, D. M. Ashcroft, K. D. Watson, K. L. Hyrich, P. R. Noyce et al., Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register, Arthritis Res Ther, vol.11, issue.2, pp.1-9, 2009.

M. S. Heiberg, W. Koldingsnes, K. Mikkelsen, E. Rødevand, and C. Kaufmann,

P. Mowinckel, The comparative one-year performance of anti-tumor necrosis factor ? drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study, Arthritis Rheum. 15 févr, vol.59, issue.2, pp.234-274, 2008.

E. Capristo, G. Addolorato, G. Mingrone, A. V. Greco, and G. Gasbarrini, Effect of disease localization on the anthropometric and metabolic features of Crohn"s disease, Am J Gastroenterol, vol.93, issue.12, pp.2411-2419, 1998.

F. Fernández-bañares, E. Cabre, F. Gonzalez-huix, and M. A. Gassull, Enteral nutrition as primary therapy in Crohn"s disease, Gut, vol.35, issue.1, pp.55-59, 1994.

P. Rutgeerts, Interventions for prevention of post-operative recurrence of Crohn"s diseasePatil-2008-The Cochrane Library-Wiley Online Library, Aliment Pharmacol Ther, vol.24, issue.s3, pp.29-32, 2006.

. Disponible,

M. A. Raebel, J. Schmittdiel, A. J. Karter, J. L. Konieczny, and J. F. Steiner, Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases: Med Care, août, vol.51, pp.11-21, 2013.

D. C. Baumgart and W. J. Sandborn, Inflammatory bowel disease: clinical aspects and established and evolving therapies. The Lancet, vol.369, pp.1641-1657, 2007.

S. Hanauer, Maintenance infliximab for Crohn"s disease : the ACCENT I randomised trial. The Lancet, p.1539, 2002.

S. B. Hanauer, W. J. Sandborn, P. Rutgeerts, R. N. Fedorak, M. Lukas et al., Human Anti-Tumor Necrosis Factor Monoclonal Antibody

, Crohn"s Disease: the CLASSIC-I Trial, Gastroenterology, vol.130, issue.2, pp.323-356, 2006.

W. J. Sandborn, B. G. Feagan, S. Stoinov, P. J. Honiball, P. Rutgeerts et al., Certolizumab pegol for the treatment of Crohn"s disease, N Engl J Med, vol.357, issue.3, pp.228-238, 2007.

S. R. Targan, S. B. Hanauer, S. J. Van-deventer, L. Mayer, D. H. Present et al., A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor ? for Crohn"s disease, N Engl J Med, vol.337, issue.15, pp.1029-1036, 1997.

S. Danese, L. Vuitton, and L. Peyrin-biroulet, Biologic agents for IBD: practical insights, Nat Rev Gastroenterol Hepatol, vol.12, issue.9, pp.537-582, 2015.
URL : https://hal.archives-ouvertes.fr/hal-01667747

G. S. Hazlewood, A. Rezaie, M. Borman, R. Panaccione, S. Ghosh et al., Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn"s Disease: A Network Meta-analysis, Gastroenterology, vol.148, issue.2, pp.344-354, 2015.

J. Salleron, S. Danese, D. Agay, L. , P. et al., Effectiveness Research in Inflammatory Bowel Disease: A Necessity and a Methodological Challenge, J Crohns Colitis, p.68, 2016.
URL : https://hal.archives-ouvertes.fr/hal-01662135

C. Ha, T. A. Ullman, C. A. Siegel, and A. Kornbluth, Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population, Clin Gastroenterol Hepatol, vol.10, issue.9, pp.1002-1009, 2012.

J. A. Cramer, A. Roy, A. Burrell, C. J. Fairchild, M. J. Fuldeore et al., Medication Compliance and Persistence: Terminology and Definitions. Value Health, vol.11, pp.44-51, 2008.

M. A. Blum, D. Koo, and J. A. Doshi, Measurement and Rates of Persistence With and Adherence to Biologics for Rheumatoid Arthritis: A Systematic Review, Clin Ther, vol.33, issue.7, pp.901-914, 2011.

K. L. Hyrich, K. D. Watson, M. Lunt, and D. Symmons, Changes in disease characteristics and response rates among patients in the United Kingdom starting anti-tumour necrosis factor therapy for rheumatoid arthritis between, Rheumatology, vol.50, issue.1, pp.117-140, 2001.

W. Kievit, J. Fransen, A. Oerlemans, H. H. Kuper, M. Van-der-laar et al., The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice, Ann Rheum Dis, vol.66, issue.11, pp.1473-1481, 2007.

M. Fabbroni, L. Cantarini, F. Caso, L. Costa, V. A. Pagano et al., Drug Retention Rates and Treatment Discontinuation among Anti-TNF-? Agents in Psoriatic Arthritis and Ankylosing Spondylitis in Clinical Practice, Mediators Inflamm, vol.2014, pp.1-7, 2014.

M. T. Osterman, K. Haynes, E. Delzell, J. Zhang, M. Bewtra et al., Comparative Effectiveness of Infliximab and Adalimumab for Crohn"s Disease, Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc, vol.12, issue.5, pp.811-817, 2014.

Å. Riis, T. C. Martinsen, H. L. Waldum, and R. Fossmark, Clinical experience with infliximab and adalimumab in a single-center cohort of patients with Crohn"s disease, Scand J Gastroenterol, vol.47, issue.6, pp.649-57, 2012.

F. Zorzi, S. Zuzzi, S. Onali, E. Calabrese, G. Condino et al., Efficacy and safety of infliximab and adalimumab in Crohn"s disease: a single centre study, Aliment Pharmacol Ther, vol.35, issue.12, pp.1397-407, 2012.

J. Cosnes, H. Sokol, A. Bourrier, I. Nion-larmurier, A. Wisniewski et al., Adalimumab or infliximab as monotherapy, or in combination with an immunomodulator, in the treatment of Crohn"s disease, Aliment Pharmacol Ther

. Sep, , 2016.

,

A. A. Saad, D. M. Ashcroft, K. D. Watson, K. L. Hyrich, P. R. Noyce et al., Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register, Arthritis Res Ther, vol.11, issue.2, pp.1-9, 2009.

M. S. Heiberg, W. Koldingsnes, K. Mikkelsen, E. Rødevand, C. Kaufmann et al., The comparative one-year performance of anti-tumor necrosis factor ? drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: Results from a longitudinal, observational, multicenter study. Arthritis Rheum, vol.59, pp.234-274, 2008.

E. Capristo, G. Addolorato, G. Mingrone, A. V. Greco, and G. Gasbarrini, Effect of disease localization on the anthropometric and metabolic features of Crohn"s disease, Am J Gastroenterol, vol.93, issue.12, pp.2411-2419, 1998.

L. Beaugerie, P. Seksik, I. Nion-larmurier, J. Gendre, and J. Cosnes, Predictors of Crohn"s Disease, Gastroenterology, vol.130, issue.3, pp.650-656, 2006.

F. Fernández-bañares, E. Cabre, F. Gonzalez-huix, and M. A. Gassull, Enteral nutrition as primary therapy in Crohn"s disease, Gut, vol.35, issue.1, pp.55-59, 1994.

P. Rutgeerts, Review article: recurrence of Crohn"s disease after surgery-the need for treatment of new lesions, Aliment Pharmacol Ther, vol.24, issue.s3, pp.29-32, 2006.

, Interventions for prevention of post-operative recurrence of Crohn"s diseasePatil-2008-The Cochrane Library-Wiley Online Library, 2016.

,

M. A. Raebel, J. Schmittdiel, A. J. Karter, J. L. Konieczny, and J. F. Steiner, Standardizing Terminology and Definitions of Medication Adherence and Persistence in Research Employing Electronic Databases: Med Care, vol.51, pp.11-21, 2013.

H. Fidder, F. Schnitzler, M. Ferrante, M. Noman, K. Katsanos et al., Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study, Gut, vol.58, issue.4, pp.501-509, 2009.